Company: LNAI
Filing Date: 2025-10-15
Form Type: DEF 14A
Source: 0001731122-25-001378
Chunk: 40

Company: Lunai Bioworks Inc.
Filing Date: 2025-10-15
Form: DEF 14A
Chunk 40
---
.                                                                                                    |

<div align='center'>25</div>

Audit Committee’s Pre-Approval Process

The Audit Committee, which has
been in place since March 28, 2018, pre-approves all audit and permissible non-audit services on a case-by-case basis. In its review of
non-audit services, the Audit Committee considers whether the engagement could compromise the independence of our independent registered
public accounting firm, and whether the reasons of efficiency or convenience is in our best interest to engage our independent registered
public accounting firm to perform the services. The Audit Committee does not delegate its responsibilities to pre-approve services performed
by our independent registered public accounting firm to management. The Audit Committee may delegate, and has delegated, pre-approval
authority to one or more of its members. The member or members to whom such authority is delegated must report any pre-approval decisions
to the Audit Committee at its next scheduled meeting.

During the fiscal year ended June
30, 2025, all services performed by Sadler were pre-approved by the Audit Committee.

Vote Required for Approval

The foregoing Proposal 3 will be
approved upon the vote of the holders of one-third of the votes cast in person or represented by proxy at the annual meeting.

Board Recommendation

The Board unanimously recommends
a vote “FOR” the ratification of Sadler, Gibb & Associates LLC as its independent registered public accounting firm for
the fiscal year 2026.

<div align='center'>PROPOSAL 4:
APPROVAL OF PROPOSED AMENDMENTS TO THE RENOVARO BIOSCIENCES, INC. 2023 EQUITY INCENTIVE PLAN</div>

General

Our Board is requesting that our
stockholders approve the proposed amendments to our Renovaro Biosciences, Inc. 2023 Equity Incentive Plan (the “”), as attached to this proxy statement as Annex A which was approved by the Board on October 12, 2025 (the “”), effective upon approval by our stockholders at the Annual Meeting. All share amounts in this proposal are
presented on a post-reverse stock split basis, reflecting the Company’s 1-for-10 reverse split effected on September 30, 2025. The
number of shares authorized for issuance under the 2023 Incentive Plan has been proportionally adjusted in accordance with the terms of
the 2023 Incentive Plan to reflect the reverse stock split.. If this proposal is approved, the